1
|
Liu CC, Wu CL, Lin MX, Sze CI, Gean PW. Disulfiram Sensitizes a Therapeutic-Resistant Glioblastoma to the TGF-β Receptor Inhibitor. Int J Mol Sci 2021; 22:ijms221910496. [PMID: 34638842 PMCID: PMC8508702 DOI: 10.3390/ijms221910496] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2021] [Revised: 09/16/2021] [Accepted: 09/24/2021] [Indexed: 02/08/2023] Open
Abstract
Despite neurosurgery following radiation and chemotherapy, residual glioblastoma (GBM) cells develop therapeutic resistance (TR) leading to recurrence. The GBM heterogeneity confers TR. Therefore, an effective strategy must target cancer stem cells (CSCs) and other malignant cancer cells. TGF-β and mesenchymal transition are the indicators for poor prognoses. The activity of aldehyde dehydrogenases (ALDHs) is a functional CSC marker. However, the interplay between TGF-β and ALDHs remains unclear. We developed radiation-resistant and radiation-temozolomide-resistant GBM models to investigate the underlying mechanisms conferring TR. Galunisertib is a drug targeting TGF-β receptors. Disulfiram (DSF) is an anti-alcoholism drug which functions by inhibiting ALDHs. The anti-tumor effects of combining DSF and Galunisertib were evaluated by in vitro cell grow, wound healing, Transwell assays, and in vivo orthotopic GBM model. Mesenchymal-like phenotype was facilitated by TGF-β in TR GBM. Additionally, TR activated ALDHs. DSF inhibited TR-induced cell migration and tumor sphere formation. However, DSF did not affect the tumor growth in vivo. Spectacularly, DSF sensitized TR GBM to Galunisertib both in vitro and in vivo. ALDH activity positively correlated with TGF-β-induced mesenchymal properties in TR GBM. CSCs and mesenchymal-like GBM cells targeted together by combining DSF and Galunisertib may be a good therapeutic strategy for recurrent GBM patients.
Collapse
Affiliation(s)
- Chan-Chuan Liu
- Institute of Basic Medical Sciences, College of Medicine, National Cheng-Kung University, Tainan 701, Taiwan;
| | - Cheng-Lin Wu
- Institute of Clinical Medicine, College of Medicine, National Cheng Kung University Hospital, National Cheng-Kung University, Tainan 701, Taiwan;
- Department of Pathology, College of Medicine, National Cheng Kung University Hospital, National Cheng-Kung University, Tainan 701, Taiwan
| | - Meng-Xuan Lin
- Department of Cell Biology and Anatomy, College of Medicine, National Cheng-Kung University, Tainan 701, Taiwan;
| | - Chun-I Sze
- Institute of Basic Medical Sciences, College of Medicine, National Cheng-Kung University, Tainan 701, Taiwan;
- Department of Pathology, College of Medicine, National Cheng Kung University Hospital, National Cheng-Kung University, Tainan 701, Taiwan
- Department of Cell Biology and Anatomy, College of Medicine, National Cheng-Kung University, Tainan 701, Taiwan;
- Correspondence: (C.-I.S.); (P.-W.G.)
| | - Po-Wu Gean
- Institute of Basic Medical Sciences, College of Medicine, National Cheng-Kung University, Tainan 701, Taiwan;
- Department of Pharmacology, College of Medicine, National Cheng-Kung University, Tainan 701, Taiwan
- Department of Biotechnology and Bioindustry Sciences, National Cheng-Kung University, Tainan 701, Taiwan
- Correspondence: (C.-I.S.); (P.-W.G.)
| |
Collapse
|
2
|
Kamble D, Mahajan M, Dhat R, Sitasawad S. Keap1-Nrf2 Pathway Regulates ALDH and Contributes to Radioresistance in Breast Cancer Stem Cells. Cells 2021; 10:E83. [PMID: 33419140 PMCID: PMC7825579 DOI: 10.3390/cells10010083] [Citation(s) in RCA: 27] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2020] [Revised: 12/22/2020] [Accepted: 12/28/2020] [Indexed: 12/15/2022] Open
Abstract
Tumor recurrence after radiotherapy due to the presence of breast cancer stem cells (BCSCs) is a clinical challenge, and the mechanism remains unclear. Low levels of ROS and enhanced antioxidant defenses are shown to contribute to increasing radioresistance. However, the role of Nrf2-Keap1-Bach1 signaling in the radioresistance of BCSCs remains elusive. Fractionated radiation increased the percentage of the ALDH-expressing subpopulation and their sphere formation ability, promoted mesenchymal-to-epithelial transition and enhanced radioresistance in BCSCs. Radiation activated Nrf2 via Keap1 silencing and enhanced the tumor-initiating capability of BCSCs. Furthermore, knockdown of Nrf2 suppressed ALDH+ population and stem cell markers, reduced radioresistance by decreasing clonogenicity and blocked the tumorigenic ability in immunocompromised mice. An underlying mechanism of Keap1 silencing could be via miR200a, as we observed a significant increase in its expression, and the promoter methylation of Keap1 or GSK-3β did not change. Our data demonstrate that ALDH+ BCSC population contributes to breast tumor radioresistance via the Nrf2-Keap1 pathway, and targeting this cell population with miR200a could be beneficial but warrants detailed studies. Our results support the notion that Nrf2-Keap1 signaling controls mesenchymal-epithelial plasticity, regulates tumor-initiating ability and promotes the radioresistance of BCSCs.
Collapse
Affiliation(s)
| | | | | | - Sandhya Sitasawad
- Redox Biology Lab, National Centre for Cell Science (NCCS), Pune 411007, India; (D.K.); (M.M.); (R.D.)
| |
Collapse
|
3
|
Song S, Li Y, Zhang K, Zhang X, Huang Y, Xu M, Li S, Guan X, Yang T, Liu Z, Jiang J, Luo Y, Lan Y. Cancer Stem Cells of Diffuse Large B Cell Lymphoma Are Not Enriched in the CD45 +CD19 - cells but in the ALDH high Cells. J Cancer 2020; 11:142-152. [PMID: 31892981 PMCID: PMC6930399 DOI: 10.7150/jca.35000] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2019] [Accepted: 09/12/2019] [Indexed: 02/07/2023] Open
Abstract
Although the existence of cancer stem cells (CSCs) has been suggested in diffuse large B cell lymphoma (DLBCL), there is still no definitive marker. CD45+CD19- has been regarded as a potential marker of CSCs in mantle cell lymphoma (MCL). So, we explored the role of CD45+CD19- in DLBCL. However, both CD45+CD19- cells and CD45+CD19+ cells did not generate tumors until more than 100,000 cells were inoculated in NOD/SCID mice, even CD45+CD19+ cells generated more and larger tumors, as well as the soft agar colony formation in vitro; The aldehyde dehydrogenase (ALDH) activity was also identified in this study. Only 1,500 ALDHhigh cells were enough to generate tumors in mice while the same number of ALDH- cells were not. Moreover, both groups formed tumors when more cells were inoculated, but ALDHhigh cells formed more and larger tumors. The similar result was obtained in vitro clonogenicity experiments. OCT4, SOX2, Nanog, and ABCG2 genes did not show any difference in CD45+CD19+, CD45+CD19-, ALDHhigh and ALDH- cells. Taken together, CSCs are not enriched in the CD45+CD19- cells but in the ALDHhigh cells in DLBCL cell lines.
Collapse
Affiliation(s)
- Shupeng Song
- Department of Infectious Disease, The First Affiliated Hospital of Harbin Medical University, Harbin, 150000, Hei Longjiang, China
| | - Yongguo Li
- Department of Infectious Disease, The First Affiliated Hospital of Harbin Medical University, Harbin, 150000, Hei Longjiang, China
| | - Kaili Zhang
- Department of Infectious Disease, The First Affiliated Hospital of Harbin Medical University, Harbin, 150000, Hei Longjiang, China
| | - Xi Zhang
- Department of Infectious Disease, The First Affiliated Hospital of Harbin Medical University, Harbin, 150000, Hei Longjiang, China
| | - Yanxin Huang
- Department of Infectious Disease, The First Affiliated Hospital of Harbin Medical University, Harbin, 150000, Hei Longjiang, China
| | - Mingyan Xu
- Department of Infectious Disease, The First Affiliated Hospital of Harbin Medical University, Harbin, 150000, Hei Longjiang, China
| | - Shuangxing Li
- Department of Infectious Disease, The First Affiliated Hospital of Harbin Medical University, Harbin, 150000, Hei Longjiang, China
| | - Xue Guan
- Animal experimental center, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150000, Hei Longjiang, China
| | - Tao Yang
- Instrument Center, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, 150000, Hei Longjiang, China
| | - Zhiyu Liu
- Central Laboratory, The First Affiliated Hospital of Harbin Medical University, Harbin, 150000, Hei Longjiang, China
| | - Jie Jiang
- Department of Pathology, The First Affiliated Hospital of Harbin Medical University, Harbin, 150000, Hei Longjiang, China
| | - Yunping Luo
- Department of Immunology, Institute of Basic Medical Science, Chinese Academy of Medical Science and Peking Union Medical College, Beijing,10005, China
| | - Yinghua Lan
- Department of Infectious Disease, The First Affiliated Hospital of Harbin Medical University, Harbin, 150000, Hei Longjiang, China
| |
Collapse
|
4
|
Yamaguchi S, Yokoyama S, Ueno M, Hayami S, Mitani Y, Takeuchi A, Shively JE, Yamaue H. CEACAM1 is associated with recurrence after hepatectomy for colorectal liver metastasis. J Surg Res 2017; 220:353-362. [PMID: 29180203 DOI: 10.1016/j.jss.2017.07.035] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2017] [Revised: 07/18/2017] [Accepted: 07/21/2017] [Indexed: 02/08/2023]
Abstract
BACKGROUND Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is re-expressed at the invasion front of colorectal cancer. CEACAM1 expression at metastatic sites remains to be investigated. The current study aims to clarify the association between CEACAM1 expression and recurrence after hepatectomy of colorectal liver metastasis and to address whether CEACAM1 induces tumor-initiating properties needed for growth at metastatic sites. METHODS Immunohistochemical analyses for CEACAM1 were performed in 67 patients with liver metastasis of colorectal cancer who had undergone curative hepatectomy. The risk factors for postoperative recurrence were calculated based on a CEACAM1 cytoplasmic domain isoform at the primary tumor invasion front. To investigate the effects of CEACAM1 cytoplasmic isoforms on HT29 and HCT116 colorectal cancer cells, Western blotting for CD44 and CD133, flow cytometry for ALDH1 activity, and soft-agar colony formation assay were performed. RESULTS CEACAM1 long (CEACAM1-L) and short (CEACAM1-S) cytoplasmic domain isoforms are strongly expressed on cancer cells in the liver metastases. Enhanced CEACAM1-S expression in the state of CEACAM1-L dominance at the primary tumor invasion front was an independent factor for colorectal cancer recurrence after curative hepatectomy. CEACAM1-4S-transfected HT29 and HCT116 cells had significantly higher CD44 expression and ALDH1 activity and increased the growth in anchorage-independent condition. CONCLUSIONS High expression of CEACAM1-S at the primary lesion invasion front is associated with recurrence and prognosis of patients with colorectal liver metastasis after curative hepatectomy. The expression of CEACAM1-4S enhances the tumor-initiating property of colorectal cancer cells.
Collapse
Affiliation(s)
- Shunsuke Yamaguchi
- Second Department of Surgery, Wakayama Medical University, School of Medicine, Wakayama, Japan
| | - Shozo Yokoyama
- Second Department of Surgery, Wakayama Medical University, School of Medicine, Wakayama, Japan.
| | - Masaki Ueno
- Second Department of Surgery, Wakayama Medical University, School of Medicine, Wakayama, Japan
| | - Shinya Hayami
- Second Department of Surgery, Wakayama Medical University, School of Medicine, Wakayama, Japan
| | - Yasuyuki Mitani
- Second Department of Surgery, Wakayama Medical University, School of Medicine, Wakayama, Japan
| | - Akihiro Takeuchi
- Second Department of Surgery, Wakayama Medical University, School of Medicine, Wakayama, Japan
| | - John E Shively
- Department of Molecular Immunology, Beckman Research Institute of the City of Hope, Duarte, California
| | - Hiroki Yamaue
- Second Department of Surgery, Wakayama Medical University, School of Medicine, Wakayama, Japan
| |
Collapse
|
5
|
Shaimerdenova M, Karapina O, Mektepbayeva D, Alibek K, Akilbekova D. The effects of antiviral treatment on breast cancer cell line. Infect Agent Cancer 2017; 12:18. [PMID: 28344640 PMCID: PMC5364572 DOI: 10.1186/s13027-017-0128-7] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2016] [Accepted: 03/16/2017] [Indexed: 12/28/2022] Open
Abstract
Background Recent studies have revealed the positive antiproliferative and cytotoxic effects of antiviral agents in cancer treatment. The real effect of adjuvant antiviral therapy is still controversial due to the lack of studies in biochemical mechanisms. Here, we studied the effect of the antiviral agent acyclovir on morphometric and migratory features of the MCF7 breast cancer cell line. Molecular levels of various proteins have also been examined. Methods To evaluate and assess the effect of antiviral treatment on morphometric, migratory and other cellular characteristics of MCF7 breast cancer cells, the following experiments were performed: (i) MTT assay to measure the viability of MCF7 cells; (ii) Colony formation ability by soft agar assay; (iii) Morphometric characterization by immunofluorescent analysis using confocal microscopy; (iv) wound healing and transwell membrane assays to evaluate migration and invasion capacity of the cells; (v) ELISA colorimetric assays to assess expression levels of caspase-3, E-cadherin and enzymatic activity of aldehyde dehydrogenase (ALDH). Results We demonstrate the suppressive effect of acyclovir on breast cancer cells. Acyclovir treatment decreases the growth and the proliferation rate of cells and correlates with the upregulated levels of apoptosis associated cytokine Caspase-3. Moreover, acyclovir inhibits colony formation ability and cell invasion capacity of the cancer cells while enhancing the expression of E-cadherin protein in MCF7 cells. Breast cancer cells are characterized by high ALDH activity and associated with upregulated proliferation and invasion. According to this study, acyclovir downregulates ALDH activity in MCF7 cells. Conclusions These results are encouraging and demonstrate the possibility of partial suppression of cancer cell proliferation using an antiviral agent. Acyclovir antiviral agents have a great potential as an adjuvant therapy in the cancer treatment. However, more research is necessary to identify relevant biochemical mechanisms by which acyclovir induces a potent anti-cancer effect. Electronic supplementary material The online version of this article (doi:10.1186/s13027-017-0128-7) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Madina Shaimerdenova
- National Laboratory Astana, Nazarbayev University, Qabanbay Batyr Avenue 53, Astana, 010000 Kazakhstan
| | - Orynbassar Karapina
- Nazarbayev University Research and Innovation System, Nazarbayev University, Astana, Kazakhstan
| | - Damel Mektepbayeva
- National Laboratory Astana, Nazarbayev University, Qabanbay Batyr Avenue 53, Astana, 010000 Kazakhstan
| | | | - Dana Akilbekova
- National Laboratory Astana, Nazarbayev University, Qabanbay Batyr Avenue 53, Astana, 010000 Kazakhstan
| |
Collapse
|
6
|
Ortiz-Sánchez E, Santiago-López L, Cruz-Domínguez VB, Toledo-Guzmán ME, Hernández-Cueto D, Muñiz-Hernández S, Garrido E, De León DC, García-Carrancá A. Characterization of cervical cancer stem cell-like cells: phenotyping, stemness, and human papilloma virus co-receptor expression. Oncotarget 2016; 7:31943-54. [PMID: 27008711 PMCID: PMC5077987 DOI: 10.18632/oncotarget.8218] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2015] [Accepted: 03/06/2016] [Indexed: 02/07/2023] Open
Abstract
Cancer stem cells (CSC) exhibit high tumorigenic capacity in several tumor models. We have now determined an extended phenotype for cervical cancer stem cells. Our results showed increased CK-17, p63+, AII+, CD49f+ expression in these cells, together with higher Aldehyde dehydrogenase (ALDHbright)activity in Cervical CSC (CCSC) enriched in cervospheres. An increase in stem cell markers, represented by OCT-4, Nanog, and β-catenin proteins, was also observed, indicating that under our culture conditions, CCSC are enriched in cervospheres, as compared to monolayer cultures. In addition, we were able to show that an increased ALDHbright activity correlated with higher tumorigenic activity. Flow cytometry and immunflorescence assays demonstrated that CCSC in cervosphere cultures contain a sub-population of cells that contain Annexin II, a Human papillomavirus (HPV) co-receptor. Taken together, under our conditions there is an increase in the number of CCSC in cervosphere cultures which exhibit the following phenotype: CK-17, p63+, AII+, CD49f+ and high ALDH activity, which in turn correlates with higher tumorigenicity. The presence of Annexin II and CD49f in CCSC opens the possibility that normal cervical stem cells could be the initial target of infection by high risk HPV.
Collapse
Affiliation(s)
- Elizabeth Ortiz-Sánchez
- 1 Subdirección de Investigación Básica, Instituto Nacional de Cancerología, Secretaría de Salud (SS), México City, Mexico
| | - Luz Santiago-López
- 1 Subdirección de Investigación Básica, Instituto Nacional de Cancerología, Secretaría de Salud (SS), México City, Mexico
| | - Verónica B. Cruz-Domínguez
- 1 Subdirección de Investigación Básica, Instituto Nacional de Cancerología, Secretaría de Salud (SS), México City, Mexico
| | - Mariel E. Toledo-Guzmán
- 1 Subdirección de Investigación Básica, Instituto Nacional de Cancerología, Secretaría de Salud (SS), México City, Mexico
| | - Daniel Hernández-Cueto
- 2 Laboratorio de Marcadores Moleculares, Hospital Infantil de México “Federico Gómez”, SA, Mexico City, Mexico
| | - Saé Muñiz-Hernández
- 1 Subdirección de Investigación Básica, Instituto Nacional de Cancerología, Secretaría de Salud (SS), México City, Mexico
| | - Efraín Garrido
- 3 Departamento de Genética y Biología Molecular, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (CINVESTAV-IPN), Mexico City, Mexico
| | - David Cantú De León
- 4 Subdirección de Investigación Clínica, Instituto Nacional de Cancerología, Secretaría de Salud (SS), México City, Mexico
| | - Alejandro García-Carrancá
- 5 Unidad de Investigación Biomédica en Cáncer, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México (UNAM) and Instituto Nacional de Cancerología, Secretaría de Salud (SS), Mexico City, Mexico
| |
Collapse
|
7
|
Kuo WY, Wu CY, Hwu L, Lee JS, Tsai CH, Lin KP, Wang HE, Chou TY, Tsai CM, Gelovani J, Liu RS. Enhancement of tumor initiation and expression of KCNMA1, MORF4L2 and ASPM genes in the adenocarcinoma of lung xenograft after vorinostat treatment. Oncotarget 2015; 6:8663-75. [PMID: 25796627 DOI: 10.18632/oncotarget.3536] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2014] [Accepted: 02/12/2015] [Indexed: 12/15/2022] Open
Abstract
Cancer stem cells (CSCs) are usually tolerant to chemotherapy and radiotherapy and associated with tumor relapse. Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor (HDACI), is currently being used in clinical trials of lung cancer. However, SAHA facilitates the formation of induced pluripotent stem cells from somatic cells. We hypothesized that SAHA would mediate the CSCs properties and subsequently confer a more malignant phenotype in lung cancer. Transfected H1299 lung cancer cells, which stably expresses a triple fused reporter gene (DsRedm-Fluc-tTKsr39) under the control of CMV promoter was used to establish a xenograft mouse model. After the treatment of SAHA, H1299 cell line and tumor xenografts were sorted by fluorescence-activated cell sorting (FACS) based on aldehyde dehydrogenase (ALDH) activity. We found that SAHA could suppress the growth of xenografted H1299 tumors with decreased proportion of ALDHbr lung cancer cells indicating that SAHA may target CSCs. However, SAHA significantly enhanced the tumor initiating capacity and the expression of malignant genes such as KCNMA1, MORF4L2 and ASPM in the remaining living ALDHbr cells. These findings suggested that SAHA treatment created a more drug-resistant state in residual ALDHbr cells. The in vivo imaging technique may facilitate searching and characterization of CSCs.
Collapse
|
8
|
Dollé L, Boulter L, Leclercq IA, van Grunsven LA. Next generation of ALDH substrates and their potential to study maturational lineage biology in stem and progenitor cells. Am J Physiol Gastrointest Liver Physiol 2015; 308:G573-8. [PMID: 25656041 PMCID: PMC4385895 DOI: 10.1152/ajpgi.00420.2014] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/24/2014] [Accepted: 02/03/2015] [Indexed: 01/31/2023]
Abstract
High aldehyde dehydrogenase (ALDH) activity is a feature of stem cells from normal and cancerous tissues and a reliable universal marker used to isolate them. There are numerous ALDH isoforms with preferred substrate specificity variably expressed depending on tissue, cell type, and organelle and cell status. On the other hand, a given substrate may be metabolized by several enzyme isoforms. Currently ALDH activity is evidenced by using Aldefluor, a fluorescent substrate likely to be metabolized by numerous ALDH isoforms. Therefore, isolation techniques based on ALDH activity detection select a heterogeneous population of stem or progenitor cells. Despite active research in the field, the precise role(s) of different ALDH isoforms in stem cells remains enigmatic. Understanding the metabolic role of different ALDH isoform in the control of stem cell phenotype and cell fate during development, tissue homeostasis, or repair, as well as carcinogenesis, should open perspectives to significant discoveries in tissue biology. In this perspective, novel ALDH substrates are being developed. Here we describe how new substrates could be instrumental for better isolation of cell population with stemness potential and for defining hierarchy of cell populations in tissue. Finally, we speculate on other potential applications.
Collapse
Affiliation(s)
- Laurent Dollé
- Liver Cell Biology Lab, Vrije Universiteit Brussel (VUB), Brussels, Belgium;
| | - Luke Boulter
- 2MRC Human Genetics Unit, Institute for Genetics and Molecular Medicine, Edinburgh, United Kingdom; and
| | - Isabelle A. Leclercq
- 3Laboratory of Hepato-Gastroenterology, Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain (UCL), Brussels, Belgium
| | - Leo A. van Grunsven
- 1Liver Cell Biology Lab, Vrije Universiteit Brussel (VUB), Brussels, Belgium;
| |
Collapse
|
9
|
Ricci F, Bernasconi S, Porcu L, Erba E, Panini N, Fruscio R, Sina F, Torri V, Broggini M, Damia G. ALDH enzymatic activity and CD133 positivity and response to chemotherapy in ovarian cancer patients. Am J Cancer Res 2013; 3:221-229. [PMID: 23593543 PMCID: PMC3623840] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2013] [Accepted: 02/21/2013] [Indexed: 06/02/2023] Open
Abstract
The prognostic/predictive role of both CD133 and Aldehyde dehydrogenase (ALDH) expression in human ovarian cancer remains elusive. This is an observational study that investigated the expression of CD133 and of ALDH enzymatic activity in fresh ovarian cancer samples and their association with different clinic-pathological patient' characteristics and explored their possible predictive/prognostic role. We analyzed the expression of CD133 and ALDH enzymatic activity in 108 human ovarian cancer samples. We found that among the total patients analyzed, 13% of them was completely negative for ALDH activity and 26% was negative for CD133 staining. Both markers were variably expressed within the samples and when both studied in the same tumor sample, no statistically significant correlation between ALDH enzymatic activity and CD133 expression was found. No statistical significant correlation was found also between the percentage values of positive ALDH and CD133 cells and the number of serial passages patient's cultures underwent, suggesting that these markers do not confer by themselves a self-renewal growth advantage to the cultures. Lower levels of CD133 were associated with higher tumor grade. No correlation with response to therapy, progression free survival and overall survival was found. Our data suggest that neither ALDH enzymatic activity nor CD133 expression provide additional predictive/prognostic information in ovarian cancer patients.
Collapse
Affiliation(s)
- Francesca Ricci
- Department of Oncology, Istituto di Ricerche Farmacologiche “Mario Negri”- IRCCSVia La Masa 19, 20156 Milan, Italy
| | - Sergio Bernasconi
- Department of Oncology, Istituto di Ricerche Farmacologiche “Mario Negri”- IRCCSVia La Masa 19, 20156 Milan, Italy
| | - Luca Porcu
- Department of Oncology, Istituto di Ricerche Farmacologiche “Mario Negri”- IRCCSVia La Masa 19, 20156 Milan, Italy
| | - Eugenio Erba
- Department of Oncology, Istituto di Ricerche Farmacologiche “Mario Negri”- IRCCSVia La Masa 19, 20156 Milan, Italy
| | - Nicolò Panini
- Department of Oncology, Istituto di Ricerche Farmacologiche “Mario Negri”- IRCCSVia La Masa 19, 20156 Milan, Italy
| | - Robert Fruscio
- Clinic of Obstetrics and Gynecology, San Gerardo Hospital, University of Milan-BicoccaVia Pergolesi 33, 20052 Monza, Italy
| | - Federica Sina
- Clinic of Obstetrics and Gynecology, San Gerardo Hospital, University of Milan-BicoccaVia Pergolesi 33, 20052 Monza, Italy
| | - Valter Torri
- Department of Oncology, Istituto di Ricerche Farmacologiche “Mario Negri”- IRCCSVia La Masa 19, 20156 Milan, Italy
| | - Massimo Broggini
- Department of Oncology, Istituto di Ricerche Farmacologiche “Mario Negri”- IRCCSVia La Masa 19, 20156 Milan, Italy
| | - Giovanna Damia
- Department of Oncology, Istituto di Ricerche Farmacologiche “Mario Negri”- IRCCSVia La Masa 19, 20156 Milan, Italy
| |
Collapse
|